Can adhesion and lower estrogen dosing make Viatris’s contraceptive patch stand out?
Viatris has patch expertise. FDA scrutiny now decides whether lower estrogen and adhesion data can turn MR-100A-01 into a real growth lever.
LGM Pharma’s $15m U.S. manufacturing expansion signals a deeper shift away from import dependence in pharma supply chains
LGM Pharma expands U.S. CDMO capacity with a $15M investment across Texas and Colorado. Explore what this means for domestic drug manufacturing. Read more.
How Kenox Pharmaceuticals is targeting the OINDP CDMO gap with integrated clinical manufacturing
Kenox Pharmaceuticals announces clinical manufacturing readiness for inhaled and nasal drug products. What this means for OINDP development timelines and IVBE strategy.